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Abstract
Repulsive guidance molecule (RGM) is a membrane-bound protein that was originally identified as an axon guidance
molecule in the chick retinotectal system. RGMa, one of the 3 isoforms found in mammals, is involved in laminar patterning,
cephalic neural tube closure, axon guidance, and inhibition of axonal regeneration. In addition to its roles in the nervous
system, RGMa plays a role in enhancing helper T-cell activation. Binding of RGM to its receptor, neogenin, is considered
necessary to transduce these signals; however, information on the binding of RGM to neogenin is limited. Using co-
immunoprecipitation studies, we have identified that the RGMa region required for binding to neogenin contains amino
acids (aa) 259–295. Synthesized peptide consisting of aa 284–293 directly binds to the extracellular domain (ECD) of
recombinant neogenin, and addition of this peptide inhibits RGMa-induced growth cone collapse in mouse cortical
neurons. Thus, we propose that this peptide is a promising lead in finding reagents capable of inhibiting RGMa signaling.
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Introduction
Repulsive guidance molecule (RGM) is a cell membrane-
associated glycosylphosphatidylinositol (GPI)-anchored glycopro-
tein that was originally identified as an axon repellent in the chick
retinotectal system [1,2]. This protein contains an N-terminal
signal peptide, an Arg-Gly-Asp (RGD) site, a partial von
Willebrand type-D (vWD) domain, and a hydrophobic domain
of unknown function [3]. It also has a putative proteolytic site, and
the cleaved carboxy-terminal mature protein is a 33-kDa fragment
[4,5]. In vertebrates, at least 3 homologues of RGM, RGMa,
RGMb (DRAGON), and RGMc (hemojuvelin HJV, HFE2), have
been identified [6,7]. RGMa is the most closely related to chick
RGM with 80% homology. Although overexpression or down-
regulation of RGM in chick tectum results in pathfinding and
mapping errors, RGMa mutant mice show normal retinal axon
projection patterns in the superior colliculus [6]. In contrast,
another study showed that RGMa functions as an axon guidance
molecule in the developing mouse hippocampus [8]. In addition,
50% of the homozygous mutant mice show defects in cephalic
neural tube closure [6]. Moreover, both in vitro and in vivo studies
have shown that RGMa inhibits axon growth [9]. RGMa
expression is induced in adult rats with a spinal cord injury
(SCI) around the lesion site, while loss of function by local
treatment with a neutralizing antibody to RGMa significantly
promotes axon regeneration after SCI.
Neogenin, the receptor for all of the RGM homologues, is a
single membrane-embedded protein originally isolated from chick
cerebellum as a homolog of deleted in colorectal cancer, a receptor
for the axon guidance cue netrin-1 [10]. Neogenin contains 4
immunoglobulin-(IgG) like and 6 fibronectin type III-(FN III)-like
domains in its extracellular region. Both netrin-1 and RGM bind
to the FN III-like domain of neogenin, but the binding affinity of
RGM for neogenin is much higher than that of netrin-1 for
neogenin [10,11]. Unfortunately, information on the binding site
on RGM for neogenin has been lacking.
In this study, we identified that the region of RGMa containing
aa 259–295 critically regulates the interaction between RGMa and
neogenin. Results from enzyme-linked immunosorbent assays
(ELISAs) revealed that the RGMa aa 284–293 directly bind to
neogenin’s extracellular domain. Furthermore, this peptide
attenuated RGMa-induced growth cone collapse in mouse cortical
neurons.
Results
C-terminus of RGMa binds to neogenin
First, we sought to determine whether the binding sites for
neogenin are located in the amino- (N-) or carboxyl- (C-) terminus
of RGMa. Deletion constructs were made consisting of Myc-
tagged human full-length RGMa (FL-RGMa-Myc), N-terminal
region of RGMa (N-RGMa-Myc), and C-terminal region of
RGMa without a GPI anchor domain (C-RGMa-Myc) (Fig. 1A).
HEK293T cells were transiently co-transfected with a control or
VSV-G-tagged full-length neogenin constructs together with each
of the RGMa constructs, and the cell lysates were immunopre-
cipitated with an anti-VSV-G antibody. Expression of FL-RGMa,
N-RGMa, and C-RGMa was observed at approximately 55, 27,
and 37 kDa, respectively, in the whole cell lysates (Fig. 1B, right
panel), although multiple bands could be seen in each lane, as
previously reported [2,9]. These multiple bands may be due to the
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RGMa is considered to have three asparagine-linked glycosylation
sites (two in the N-terminus and one in the C-terminus) [12]. FL-
RGMa-Myc and C-RGMa-Myc co-immunoprecipitated with
VSVG-Neogenin (Fig. 1B); however, N-RGMa did not. These
results show that the C-terminus, but not the N-terminus of
RGMa binds to neogenin.
Neogenin-binding site resides between the vWD and the
hydrophobic domain of RGMa
To more precisely determine the neogenin-binding site of
RGMa, expression vectors encoding various fragments of Myc-
tagged C-RGMa were generated (Fig. 1C), and their ability to
bind to neogenin was assessed using co-immunoprecipitation as
described above. Our results show that deletion of aa 169–258,
including the vWD domain (C-RGM1), did not affect binding
(Fig. 1D), while deletion of aa 169–332 (C-RGMa2) did,
suggesting that the neogenin-binding site is localized within aa
259–332. To further pinpoint the neogenin-binding site of RGMa,
shorter fragments were designed. Although some of the fragments
were hardly expressed probably due to their shorter lengths,
expression of 3 fragments—C-RGMa3, C-RGMa4, and C-
RGMa5 (for sequences refer to Fig. 1C)—was detectable
(Fig. 1E). Despite their limited expression, bands for C-RGMa3
and C-RGMa4 were clearly detected in the IP lanes (Fig. 1E),
whereas C-RGMa5 did not co-immunoprecipitate with VSVG-
Neogenin. Taken together, these results show that RGMa
fragments containing aa 259–295 interact with neogenin, while
fragments lacking this domain do not. Our immunoprecipitation
experiments demonstrate that the RGMa domain required for
binding to neogenin is within aa 259–295.
Determination of the core binding site by ELISA
Direct binding of different RGMa peptide fragments to
neogenin was assessed by ELISA. Six peptides (each 10-aa long)
derived from aa 257–310 of RGMa (Fig. 2A) were assessed for
their ability to bind to neogenin. Each RGMa peptide was coated
on the ELISA plate, and then recombinant Fc-fused neogenin
ECD or neurotrophin receptor p75 (p75NTR) ECD (negative
control) was added. The results in Fig. 2B show that peptide 4 (aa
284–293) had a significantly higher binding affinity for neogenin
compared with other RGM peptides. Peptide 3 showed some
tendency to bind to neogenin, but this was not significant. Thus,
we concluded that aa 284–293 of RGMa binds to neogenin.
Figure 1. The RGMa domain required for binding to neogenin is within aa 259–295. (A and C) Schematic representation of RGMa and its
deletion mutants are shown with their domain structures. Arrowhead shows potential cleavage site. SP: signal peptide, vWD: von Willebrand factor
type-D domain, HD: hydrophobic domain, GPI: GPI-anchor. (B, D, and E) Co-immunoprecipitation of full-length neogenin-VSV-G with the deletion
mutants of RGMa-Myc. HEK293T cells were transiently transfected with the indicated plasmids. Cell lysates were immunoprecipitated with the anti-
VSV-G antibody. The immunoprecipitates (IP) and cell lysates (Lysates) were analyzed by western blotting with anti-Myc and anti-VSV-G antibodies.
doi:10.1371/journal.pone.0032791.g001
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Our results suggest that peptide 4 binding to neogenin either
elicits or inhibits downstream RGMa signaling. To clarify this
issue, we performed a growth cone collapse assay, since addition of
RGMa to cultured cortical neurons has been shown to cause the
collapse of their growth cones [13]. We cultured cortical neurons
from E18 mouse for 48 h to allow sufficient neurite growth for
growth cone evaluation. Recombinant RGMa was then added to
the culture with or without peptide 4 (Fig. 3A and B). RGMa
stimulation significantly induced growth cone collapse compared
with the control (without RGMa stimulation). Addition of peptide
4 abolished the effect of RGMa, whereas addition of peptide 4 by
itself did not affect growth cone behavior. We synthesized two
peptides (peptide A and peptide B) as negative controls. Peptide A
is a scrambled derivative of peptide 4, whereas peptide B includes
aa 230–239 and is a part of the RGMa C-terminus but is not
included in C-RGMa4. These peptides did not modulate RGMa-
induced growth cone collapse (Fig. 3A). These results demonstrate
that peptide 4 attenuates the effect of RGMa on the neurons, but
does not act as an RGMa agonist.
Discussion
Through co-immunoprecipitation studies we have shown here
for the first time that the RGMa region containing aa 259–295 is
sufficient for binding to neogenin. Moreover, we identified that the
region containing aa 284–293 critically regulates the interaction
between RGMa and neogenin. Our results also underline the
physiological importance of this interaction since inhibition of this
interaction by addition of RGM peptide 4 described here can
attenuate the RGM-induced inhibitory effect on cortical neurons.
We demonstrate that peptide 4 attenuated the effect of RGMa
on the neurons, but did not work as an RGMa agonist. Therefore,
this sequence by itself may not be sufficient for the signal
transduction mediated by RGMa to neogenin. We could not
detect the inhibition of RGMa binding to neogenin by peptide 4 in
the transfected cells by using co-immunoprecipitation (data not
shown). It is possible that RGMa has multiple binding sites.
However, we would like to note that the sequence we identified is
functionally important. Because peptide 4 attenuated the effect of
RGMa on growth cone behavior, our data demonstrate that
peptide 4 sequence is required for RGMa-mediated signal
transduction.
In vertebrates, 3 homologues of RGM, RGMa, RGMb, and
RGMc, have been found. RGMs share common structural
features, including an N-terminal signal peptide; an RGD site,
which may be associated with cell attachment; a partial vWD
domain; a hydrophobic domain; and a C-terminal end necessary
for attaching the protein to the cell membrane via a GPI-anchor
[2,3]. The identified binding site of RGM for neogenin is not
Figure 2. RGMa aa 284–293 are critical for the interaction with neogenin. (A) Sequence alignment of the synthesized RGMa peptide.
Peptides 1–6 were designed within aa 257–310, which is the region required for the interaction between RGMa and neogenin as shown in Fig. 1. (B)
RGMa peptide 4 (aa 284–293) directly binds to neogenin’s ECD. Relative binding of each RGMa peptide to ELISA plates coated with neogenin-ECD-Fc
is shown. p75NTR-Fc was used as a control. Results (%) are shown as the mean 6 SEM of 3 independent experiments (**P,0.01, *P,0.05).
doi:10.1371/journal.pone.0032791.g002
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highly conserved, at least in rat and chick RGMa, suggesting that
this sequence could be physiologically important.
The RGM-neogenin interaction regulates various functions in
the developing central nervous system (CNS), such as pathfinding
of retinotectal projection [14], neuronal cell death [15], and neural
tube closure [6]. In addition, RGM expression is induced after
injury to the adult CNS [16,17]. We have reported that inhibition
of RGMa signaling by treatment with an anti-RGMa blocking
antibody enhances axon regeneration and promotes functional
recovery after spinal cord injury [9]. Furthermore, we recently
reported that RGMa is expressed in dendritic cells, and neogenin
is expressed in helper T cells [18]. RGMa enhances helper T-cell
activation via dendritic cells both in vitro and in vivo. Importantly,
inhibition of RGMa signals by neutralizing antibody blocked
experimental autoimmune encephalomyelitis and T-cell activation
Figure 3. RGMa peptide 4 (aa 284–293) inhibits RGMa-induced growth cone collapse. (A) Effects of RGMa peptide 4 on RGMa-induced
growth cone collapse. Cortical neurons were treated with RGMa and/or RGMa peptides for 30 min. The results were quantified from 3 independent
experiments, and the percentage of collapsed growth cones is shown (**P,0.01). Pep4, peptide 4; PepA, Peptide A; PepB, peptide B. (B)
Representative images of growth cones. Red: Phalloidin, Green: Tuj1. Scale bar: 10 mm.
doi:10.1371/journal.pone.0032791.g003
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subjects. These findings suggest that RGMa is a promising
molecular target to treat CNS injury, as well as, multiple sclerosis.
Based on these observations, the peptide developed here could be
used as a peptide lead for drug discovery.
Since the neogenin-binding site on RGM is located within aa
284–293, and the peptide based on this sequence inhibits RGM
signaling in vitro, it seems likely that this peptide competitively
inhibits the interaction between RGM and neogenin, thereby
leading to attenuation of the effect of RGMa on neurons. The
identified neogenin-binding site on RGMa is different from the
antigen sequence of the anti-RGMa neutralizing antibody
previously reported [9]. Supporting our findings in the present
study, this neutralizing antibody does not inhibit the binding of
RGMa to neogenin (unpublished data), suggesting that the region
recognized by the antibody may be important for the receptor
function. For example, it is possible that this region is required for
interaction of neogenin with its co-receptor Unc5B [13]. Future
study will determine functionally important domains in RGMa by
elucidating the protein structure of RGMa.
Our findings provide important information on the function of
RGMa and suggest that small molecules, peptides, and neutral-
izing antibodies targeting the region of RGMa identified in this
study would be effective in blocking RGMa signaling in vivo. These
reagents may be used to treat patients with spinal cord injury and
multiple sclerosis.
Materials and Methods
The Institutional Animal Care and Use Committees of
Graduate School of Medicine, Osaka University approved all
experimental procedures (19-081-0).
Antibodies and reagents
The following primary antibodies were used in this study: Myc-
tag (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA) and
vesicular stomatitis virus glycoprotein (VSV-G)-tag (1:1,000;
Sigma-Aldrich, St. Louis, MO). Horseradish peroxidase (HRP)-
conjugated anti-mouse and anti-rabbit IgG secondary antibodies
(Cell Signaling Technology, Danvers, MA, USA), and the ECL
plus system (GE Healthcare Chalfont St Giles, England) were used
for detection.
Plasmid constructs
To generate a secreted form of RGMa, cDNA corresponding to
human RGMa (aa 1–422), which lacks a C-terminal GPI anchor
region was generated [19]. The constructs FL-RGMa, N-RGMa,
C-RGMa1, C-RGMa2, C-RGMa3, C-RGMa4, and C-RGMa5
(sequence information is provided in Fig. 1C) were cloned into
pSecTag2C/Hygro (Invitrogen, Carlsbad, CA, USA). All con-
structs were verified by DNA sequencing. VSV-G-tagged human
neogenin in pcDNA 3.1 was a kind gift from Dr. Eric R Fearon
[20,21,22].
Cell culture and transfection
HEK293T cells (ATCC, Manassas, VA) were cultivated in
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supple-
mented with 10% (v/v) fetal bovine serum (FBS) and penicillin/
streptomycin (Invitrogen). These cells were transfected with
lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions.
For cortical neurons, E18 mouse embryo cortices were isolated
and dissociated with 0.25% trypsin (Invitrogen) and 0.5 mg/mL
DNase1 (Sigma-Aldrich, St Louis, MO, USA) for 15 min at 37uC.
DMEM (Invitrogen) containing 10% FBS was added, and the cells
were centrifuged at 1,000 rpm for 4 min. Neurons were plated on
poly-L-lysine-coated chamber slides and maintained in DMEM/
F12 medium containing B27 supplement (Invitrogen) at 37uCi n
an atmosphere of 5% CO2.
Co-immunoprecipitation
For co-immunoprecipitation of neogenin with RGMa,
HEK293T cells were transfected with VSV-G-tagged neogenin
and Myc-tagged RGMa constructs and incubated for 36–48 h.
After washing, the cells were lysed in 1% Triton X-100, 150 mM
NaCl, 20 mM Tris/HCl (pH 7.5), complete EDTA-free protease
inhibitors (Roche Diagnostics, Basel, Switzerland), and 1 mM
phenylmethylsulfonyl fluoride. VSV-G antibody (2 mg) was added
to the cell lysates and incubated for 4 h under rotation at 4uC
followed by the addition of protein A-sepharose beads (GE
Healthcare) and a second 4-h incubation under rotation at 4uC.
Protein precipitates were washed several times, and were then
separated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and immunoblotted to detect Myc-tagged RGMa.
Peptide synthesis
Six peptides were synthesized (SIGMA Life Science, Japan) for
use in ELISA. Each peptide consisted of 10 aa encoding RGMa
(covering aa 257–315, Fig. 2A) fused with an N-terminal TAT
protein (YGRKKRRQRRR). RGMa peptide 4 without a TAT
protein was synthesized in the same way and was used in the
growth cone collapse assay. For growth cone collapse assay, three
peptides were synthesized in the same way. Peptide 4 without
TAT protein; peptide A, scrambled peptide of peptide 4
(QLGYFRVATR); and peptide B, aa 230–239. Peptide A and B
were used as negative controls.
ELISA
ELISAs were performed using 96-well microplates (Thermo
Fisher Scientific, Waltham, MA, USA) coated with 0.1% bovine
serum albumin (BSA)/phosphate-buffered saline (PBS) or synthet-
ic RGMa peptides (5 mg/mL, 100 mL/well) for 16 h at 4uC. After
washing with PBS, the wells were blocked for 1 h with 5% BSA/
PBS. Recombinant mouse neogenin-Fc chimera protein (R&D
Systems, Minneapolis, MN, USA) or p75-Fc chimera protein
(R&D systems) as a control was then added (1 mg/mL, 100 mL/
well) to the plates. One hour after incubation, the plates were
washed, and anti-IgG Fc antibody was added. HRP-conjugated
secondary antibodies, substrate reagent, and stop solution (R&D
Systems) were used to detect protein binding. Absorbance was
measured at 450 nm.
Growth cone collapse assay
Cortical neurons were isolated from E18 mouse embryos and
plated onto 3.5-cm dishes coated with poly-L-lysine (100 mg/mL,
Sigma-Aldrich). Cells were cultured in an incubator gassed with
5% CO2 in DMEM/F12 medium containing B27 supplement
(Invitrogen). After 48 h in culture, cells were treated with
recombinant RGMa (2 mg/mL) and/or RGMa-peptide 4 (1 mM)
for 30 min. Cells were fixed with 0.5% glutaraldehyde for 30 min
at room temperature and treated with PBS containing 5% BSA
and 0.1% Triton X-100. The cells were then incubated with anti-
neuronal class III ß-tubulin (Tuj1, 1:5000; Covance Laboratories,
Inc., Berkeley, CA, USA) and rhodamine-phalloidin (Invitrogen)
for 2 h at room temperature, and secondary anti-mouse IgG
antibody conjugated with Alexa Fluor 488 (Invitrogen) for 1 h at
room temperature. Neurons were analyzed using an OLYMPUS
Identification of RGMa-Neogenin Binding Site
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total loss of filopodia and lamellipodia.
Statistical analysis
In Fig. 2B and 3A, the results (n=3) were analyzed using single-
factor analysis of variance followed by Scheffe’s multiple
comparison test. P values of less than 0.05 were considered
significant.
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